Literature DB >> 8611817

Treatment resistance in schizophrenia.

E C Johnstone, R Sandler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8611817      PMCID： PMC2350259          DOI： 10.1136/bmj.312.7027.325

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  7 in total

1.  Short-term outcome in trial entrants and trial eligible patients.

Authors:  J F MacMillan; T J Crow; A L Johnson; E C Johnstone
Journal:  Br J Psychiatry       Date:  1986-02       Impact factor: 9.319

Review 2.  Functional imaging and cognitive abnormalities.

Authors:  C Frith
Journal:  Lancet       Date:  1995-09-02       Impact factor: 79.321

3.  Recent developments in the drug treatment of schizophrenia.

Authors:  J M Davis
Journal:  Am J Psychiatry       Date:  1976-02       Impact factor: 18.112

4.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

5.  A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.

Authors:  G Chouinard; B Jones; G Remington; D Bloom; D Addington; G W MacEwan; A Labelle; L Beauclair; W Arnott
Journal:  J Clin Psychopharmacol       Date:  1993-02       Impact factor: 3.153

Review 6.  Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4.

Authors:  P Seeman
Journal:  Neuropsychopharmacology       Date:  1992-12       Impact factor: 7.853

7.  Clozapine-induced agranulocytosis. Incidence and risk factors in the United States.

Authors:  J M Alvir; J A Lieberman; A Z Safferman; J L Schwimmer; J A Schaaf
Journal:  N Engl J Med       Date:  1993-07-15       Impact factor: 91.245
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.